Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer – Authors' reply
Vivek Subbiah, Ulrik Lassen, Eduard Gasal, Paul Burgess, Zev A. Wainberg
Topics & Concepts
TrametinibDabrafenibMedicineBiliary tract cancerOncologyInternal medicineCancerBiliary tractMEK inhibitorGastroenterologyKinaseMAPK/ERK pathwayBiologyVemurafenibGemcitabineGeneticsMetastatic melanomaCholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct DisordersCancer Mechanisms and Therapy